Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
← catalyst calendarNCT07793422 · readout ≤ 3,046 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
370estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-11-29 | estimated | When the study began enrolling |
| Primary completion | Dec 2034 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2034 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Amyloid Light Chain (AL) Amyloidosis
Interventions
- Drug: Etentamig
- Drug: Daratumumab
- Drug: Cyclophosphamide
- Drug: Bortezomib
- Drug: Dexamethasone
- Drug: Bortezomib
- Drug: Cyclophosphamide
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events
measured Up to Approximately 96 Months
Randomized Portion: Complete Hematologic Response (HemeCR) Rate
measured Up to Approximately 60 Months
Randomized Portion: Major Organ Deterioration Progression-Free Survival (MOD-PFS)
measured Up to Approximately 60 Months
Related
ABBV · their whole pipeline · Who in Congress owns ABBV? · Executive-branch trades in ABBV
ABBV's other studiesmost recently updated first
- Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma Phase 2 · Completed
- A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) Phase 1 · Active, not recruiting
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 2/3 · Recruiting
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer Phase 3 · Recruiting
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Phase 2/3 · Recruiting
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed